Okami Medical Announces Closing of $7.2M Series D Financing

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

June 24, 2020

Okami Medical Inc., announced today the close of a Series D financing totaling $7.2 million.

Okami Medical notes the financing was led by U.S. Venture Partners and was joined by members of Okami’s board of directors and medical device industry veterans.

The financing provides Okami Medical, the second portfolio company of medical device incubator Inceptus Medical LLC, with capital to commercialize its innovative catheter-based technologies for peripheral vascular occlusion. To date, Okami Medical has developed the LOBO™ Vascular Occlusion System, which is uniquely designed to provide interventional physicians with a single-device, one-and-done solution for the occlusion of a wide range of arterial targets without the need for multiple embolic devices.

“We are pleased to continue to work with investors who have supported us in our mission to create and foster innovative concepts into successful companies, including Inari Medical (Inceptus’ first portfolio company, publicly traded on the Nasdaq Global Select Market under the symbol “NARI”), Sequent Medical (acquired by Terumo in 2016) and MicroVention (acquired by Terumo in 2006),” said Bob Rosenbluth, PhD, President and CEO of Okami.  “We will use these funds to support and accelerate Okami’s commercial and technology development programs.”

The LOBO (LOw-profile Braided Occluder) system combines a patented design with proprietary HDBRAID™ technology to create a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure. The advanced technology platform enables the fast and efficient closure of blood vessels throughout the body for the successful treatment of a diverse set of conditions. The LOBO system is 510(k) cleared by the U.S. FDA for the occlusion of peripheral arteries.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.